Crystal Nyitray, PhD is the founder and CEO of Encellin, a biotechnology company pioneering the future of living medicine—where cells themselves become therapeutics, dynamically sensing and responding to disease. With a vision to move beyond daily medications and into cell-based treatments that continuously adapt and deliver therapy from within the body, Encellin is unlocking a new era of regenerative medicine. Dr. Nyitray earned her PhD in Chemistry and Chemical Biology from the University of California, San Francisco (UCSF), specializing in biomaterials and cell-based therapeutics. Under her leadership, Encellin’s first clinical program is advancing a therapy for type 1 diabetes, with a broader platform aimed at transforming treatment for multiple chronic diseases. A recognized leader in cell therapy and regenerative medicine, Dr. Nyitray has authored over 25 patents and led Encellin to recognition from leading organizations, including MedTech Innovator, Rosenman Innovators, and the American Diabetes Association Innovator Award. She was also part of the inaugural cohort of UCSF Rosenman RISE founders in 2022. Beyond her work in biotech, Dr. Nyitray is an avid runner, bringing the same endurance and resilience to both the trails and the lab. She is also committed to mentoring the next generation of biotech innovators and fostering a more inclusive and dynamic ecosystem in healthcare innovation.